How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

401. G207 Followed by Radiation Therapy in Malignant Glioma

in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment Required steroid increase within 2 weeks prior to injection HIV seropositive Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir) Active oral or genital herpes lesion Any contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc

2005 Clinical Trials

402. A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients

or suspected to be immunocompromised (e.g., subjects receiving immunosuppressive therapy or chemotherapy for malignancy, or are seropositive for HIV). Received an investigational drug in the 30 days prior to the study. Receiving systemic antiviral or immunomodulatory treatments. Must not have received systemic antiviral treatments (e.g., valaciclovir, Famvir (famciclovir), acyclovir, lysine) within 3 days of starting study drug or immunomodulatory treatments in the 30 days before starting study drug (...) . Clinically significant impaired renal function as defined by a creatinine clearance <30 ml/min, calculated using the Cockcroft-Gault formula. Clinically significant impaired hepatic function defined as an ALT (alanine transaminase) level > 5 times the normal upper limit. Subjects with active liver disease. Known to be hypersensitive to acyclovir, famciclovir, ganciclovir or any component of valaciclovir formulations. Known resistance to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir

2005 Clinical Trials

403. A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: HIV seropositive and HSV-2 seropositive MSM (men having sex with men) 18 years old or older Exclusion Criteria: Known history of adverse reaction to acyclovir or valacyclovir Planned open label use of acyclovir, valacyclovir or famciclovir Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2005 Clinical Trials

404. Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome

pneumonia. Immunocompromised patients at risk of opportunistic infection (e.g., patients with HIV infection, underlying malignancy, or who have received chemotherapy or immunosuppressive drugs within 30 days.) Patients who have or will receive any systemic antiviral medication (other than acyclovir, famciclovir, amantadine or rimantadine), systemic corticosteroids equivalent to approximately 0.5mg/kg prednisone, or any investigational drug within 30 days before enrollment or during treatment. Any period

2005 Clinical Trials

405. A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

-month study. Laboratory confirmation of genital herpes (a positive Herpes Simplex Virus-2 antibody test). 3 or more outbreaks of genital herpes in the previous 12 months if not on genital herpes medicines currently. 3 or more outbreaks of genital herpes per year in the period prior to beginning of treatment for chronic genital herpes. Exclusion Criteria: Kidney diseases. Liver diseases. Known allergic reactions to VALTREX (valaciclovir), ZOVIRAX (acyclovir), FAMVIR (famciclovir), or CYTOVENE

2004 Clinical Trials

406. Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B

or thymosin), systemic cytotoxic agents, chronic anti-viral agents excluding lamivudine (e.g. ganciclovir, adefovir dipivoxil, entecavir, famciclovir, FTC, DAPD, LFMAU, HBIg), Chinese herbal medicines known to have activity against HBV within the previous 12 months or during the study; use of agents with effect of ALT reduction (e.g. schisandra agents) during the study Use of lamivudine within the previous 3 months or during the study Planned for liver transplantation or previous liver transplantation

2006 Clinical Trials

407. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. (PubMed)

A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. Efficacy of oral antiviral therapies, ie, acyclovir, valacyclovir (VACV), and famciclovir, for suppression of recurrent genital herpes was studied at different doses and regimens.We sought to compare the clinical efficacies of the different oral antiviral drugs prescribed prophylactically to suppress recurrent genital herpes.MEDLINE and EMBASE databases were searched for articles on genital (...) evaluated regimens, with comparable efficacies, were given twice daily, ie, acyclovir (400 mg twice daily), VACV (250 mg twice daily), and famciclovir (250 mg twice daily), or once daily (VACV 500 mg).The only end point available for all the studies was the number of patients presenting at least one recurrence of genital herpes during the observation period.The results of this first meta-analysis confirmed the high clinical efficacy of oral acyclovir, VACV, or famciclovir for prophylaxis against

2007 Journal of the American Academy of Dermatology

408. ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, or generalized malignancy. Subjects with a history of cancer who are not on active treatment and are not thought to have a weakened immune system at the time of enrollment will be eligible Any active use of non-topical antiviral therapy including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, brivudine, and cidofovir Contacts and Locations Go

2007 Clinical Trials

409. Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir. Subject has had a herpes vaccine. Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device. Subject has previously participated in the current study (TPI-H-221). Subject requires chronic use of analgesics, pain medication or non-steroidal anti-inflammatory agents (NSAIDs). Subject has a recent history of renal dysfunction or serious hepatic disease. Subject has

2007 Clinical Trials

410. Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients

by the investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results. Use of immunosuppressive therapy, immunomodulatory therapy (including interferon or thymosin), systemic cytotoxic agents within the previous 6 months or during the study. Use of chronic anti-viral agents(e.g. lamivudine, adefovir dipivoxil, entecavir, famciclovir, tenofovir, FTC, ganciclovir, DAPD, LfMA, HBIg, etc.), Chinese herbal medicines known to have activity against HBV within

2007 Clinical Trials

411. Effectiveness of Acyclovir in Suppressing HIV Viral Load in Women Coinfected With HIV and Herpes Simplex Virus Type 2 (HSV-2)

Initiating HAART per Peruvian guidelines for the first time at study entry CD4 count less than 200 cells/mm3 OR CD4 count less than 350 cells/mm3 AND viral load greater than 55,000 copies/ml within 30 days prior to study entry Does not intend to move outside of greater metropolitan Lima, Peru area for the duration of the study Willing to follow all study requirements Willing to provide written informed consent Exclusion Criteria: Prior HAART History of adverse reaction to acyclovir, famciclovir (...) , or valacyclovir Unwilling to take acyclovir, famciclovir, or valacyclovir History of seizures Renal insufficiency, defined as serum creatinine greater than 2 mg/dl or a creatinine clearance less than 50 ml/min Treatment for a serious medical condition 14 days prior to study entry. Patients with chronic, acute, or recurrent opportunistic infections (OIs) who have completed therapy and are clinically stable on therapy for at least 14 days prior to study entry are not excluded. Clinically unstable and untreated

2006 Clinical Trials

412. Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

[TDF], emtricitabine (FTC), clevudine, telbivudine [LdT], famciclovir), or any other experimental anti-HBV antiviral agent Therapy with interferon, thymosin alpha or other immunostimulators within 24 weeks of enrollment (i.e., dosing) into this study Subjects who require chronic administration of concomitant medications which cause immunosuppression or which are associated with a high rate of nephrotoxicity or hepatotoxicity, or which affect renal excretion, should not be enrolled in this study

2006 Clinical Trials

413. Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients

medications during the 12 month observation period of the study are: Virustatic drugs, active against CMV: Foscarnet, Cidofovir (HPMPC), Acyclovir, Valaciclovir, Famciclovir/Penciclovir, Lobucavir, Antisense compound Antimetabolites: Fluorouracil, Mercaptopurine, Methotrexate, Thioguanine, Hydroxurea Alkylating substances: Busulfan, Carmustine, Chlorambucil, Cisplatin, Cyclophosphamide, Dacarbazine (DTIC), Lomustine, Mechlormethamine, Melphalan, Streptozotocin, Tiothepa, Uracil mustard anti CMV

2006 Clinical Trials

414. Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

in the 12 months before Screening for this study. Has a medical condition that required prolonged or frequent use of systemic acyclovir or famciclovir. Has a medical condition that requires frequent or prolonged use of systemic corticosteroids although inhaled or intra-articular corticosteroids are allowed. Has a medical condition requiring the chronic or prolonged use of potentially hepatotoxic drugs or nephrotoxic drugs. Is currently abusing alcohol or illicit drugs or has a history of alcohol abuse

2006 Clinical Trials

415. HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.

history of adverse reaction to valacyclovir, acyclovir or famciclovir; Planned open label use of acyclovir, valacyclovir, or famciclovir Known medical history of seizures Known renal failure, serum creatinine >2.0mg/dl Hematocrit < 30 % Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2006 Clinical Trials

416. Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease

protocol. For HIV-infected participants, a stable antiretroviral regimen for the past 6 months Exclusion Criteria: Concurrent Kaposi sarcoma or non-hodgkin's lymphoma A history or evidence of CMV disease Hypersensitivity to ganciclovir or valganciclovir Use of high-dose acyclovir (>800 mg bid), valacyclovir (>1000 mg qd) or famciclovir (>1000 mg qd), ganciclovir, foscarnet, or cidofovir Neutropenia (ANC <1500) Renal insufficiency with serum creatinine > 1.5 mg/ml or CrCl < 60 AST or ALT > 5 times upper

2006 Clinical Trials

417. Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial

but previously treated with placebo in the L-FMAU-301, L-FMAU-302. Patients who were currently receiving antiviral, immunomodulatory or corticosteroid therapy. Patients previously treated with interferon, lamivudine, lobucavir, famciclovir, adefovir or any other investigational nucleoside for HBV infection. Patients with a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patients co-infected with HCV, HDV or HIV. Patients with a liver mass (hemangioma, nodule), biliary diseases except

2006 Clinical Trials

418. Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection

with the study requirements. Exclusion Criteria: Patient is currently receiving antiviral, immunomodulatory or corticosteroid therapy. Patients previously treated with lamivudine, lobucavir, adefovir, famciclovir, or any other investigational nucleoside for HBV infection. Previous treatment with interferon must have ended at least 6 months prior to the screening visit. Patient has a history of ascites, variceal hemorrhage or hepatic encephalopathy. Patient is co-infected with HCV or HIV. Patient has evidence

2006 Clinical Trials

419. Atypical herpes simplex infection masquerading as recalcitrant pemphigus vulgaris. (PubMed)

. Dramatic resolution was observed and the patient has remained free of disease for 13 months while taking only prophylactic famciclovir.

2007 Australasian Journal of Dermatology

420. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. (PubMed)

and/or famciclovir. Four of six patients with HBIG breakthrough without nucleoside analogue treatment failure yielded potentially significant HBsAg mutations post transplant. These data do not support previous reports highlighting the disappearance of HBsAg mutants in liver transplant recipients after discontinuation of HBIG. Determination of HBV genotype, as well as identification of HBV polymerase and S gene mutations in liver transplant candidates may be warranted to optimize HBV management strategies post

2003 American Journal of Transplantation

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>